News
Synergy Pharmaceuticals Announces Closing of Merger With Callisto Pharmaceuticals
NEW YORK, Jan. 17, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today announced that its previously
Synergy Pharmaceuticals Announces Approval of Merger With Callisto Pharmaceuticals and Other Actions at Annual Meeting of Stockholders
NEW YORK, Jan. 15, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP) ("Synergy") today announced that it convened its annual meeting of stockholders yesterday and it has received
Formulaire de déclaration mensuelle des droits de vote - Décembre 2012
Le 8 janvier 2013
Publication
du nombre d'actions composant le capital et du nombre total de droits de vote
(articles L. 233-8 II du code de commerce et 223-16 du règlement général
Bilan semestriel du contrat de liquidité Boiron au 31 décembre 2012
le 2 Janvier 2013
Bilan semestriel du contrat de liquidité BOIRON contracté avec NATIXIS
Au titre du contrat de liquidité confié à NATIXIS portant sur les actions
BG Medicine annonce l'obtention de la marque CE et le lancement de la version automatisée du test BGM de la Galectine-3
Introduction du premier test automatisé en Europe et dans les territoires reconnaissant la marque CE
WALTHAM, Massachussetts, 4 janvier 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc.
Synergy Announces Positive Results From Plecanatide Phase IIb/III Trial in Patients With Chronic Idiopathic Constipation
Topline Data Show That Plecanatide Met Primary and Key Secondary Endpoints
NEW YORK, Jan. 2, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP) today announced that plecanatide, its
BG Medicine Announces Obtaining CE Mark and Launching of Automated BGM Galectin-3 Test
First Automated Test Launches in Europe and Territories Recognizing the CE Mark
WALTHAM, Mass., Jan. 3, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development
Synergy Pharmaceuticals Completes Phase I Trial of SP-333, a Second-Generation GC-C Agonist to Treat Gastrointestinal Diseases
NEW YORK, Dec. 28, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, announced today the successful
Synergy Pharmaceuticals Begins Phase IIb Trial of Plecanatide in Irritable Bowel Syndrome With Constipation (IBS-C)
NEW YORK, Dec. 27, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, announced today that dosing has
Share capital reduction of Boiron
SHARE CAPITAL REDUCTION OF BOIRON
THROUGH CANCELLATION OF THE SHARES BOUGHT IN THE FRAME OF
THE SHARE BUYBACK PROGRAM
The Board of Directors of December 19, 2012 has decided to reduce the
Réduction du capital social de Boiron
REDUCTION DU CAPITAL SOCIAL DE BOIRON
PAR ANNULATION DES ACTIONS ACQUISES DANS LE CADRE DU PROGRAMME DE RACHAT D'ACTIONS
Le Conseil d'administration du 19 décembre 2012 a
Cession par la société Pierre Fabre S.A. de sa participation dans Boiron
Le 17 décembre 2012, avant ouverture de la bourse, la société PIERRE FABRE SA a cédé hors marché sa participation dans BOIRON (soit 3 330 436 actions)
Assignment by the company Pierre Fabre S.A. of its shareholding in Boiron
On December 17, 2012, before opening of the stock exchange market, the company PIERRE FABRE SA assigned off the market its shareholding in BOIRON (i.e. 3,330,436 shares) to the benefit of some members
Synergy Pharmaceuticals Presents Poster on Novel Mechanism of Action of SP-333, an Agonist of Guanylate Cyclase-C for Treatment of Ulcerative Colitis
Scientific Poster Presentation at 2012 Advances in IBD Conference
NEW YORK, Dec. 14, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal
Formulaire de déclaration mensuelle des droits de vote - Novembre 2012
Le 6 décembre 2012
Publication
du nombre d'actions composant le capital et du nombre total de droits de vote
(articles L. 233-8 II du code de commerce et 223-16 du règlement général
CESSION PAR LA SOCIETE PIERRE FABRE SA DE SA PARTICIPATION DANS BOIRON
La société PIERRE FABRE SA a manifesté son intention de céder l'intégralité de sa participation de 15,5% dans BOIRON (3 330 436 actions), participation
ASSIGNMENT BY THE COMPANY PIERRE FABRE SA OF ITS SHAREHOLDING IN BOIRON
The company PIERRE FABRE SA has expressed its intention to assign the entirety of its shareholding of 15.5% (i.e. 3,330,436 shares) in BOIRON, acquired through the merger between DOLISOS and BOIRON in
Formulaire de déclaration mensuelle des droits de vote - Octobre 2012
Le 9 novembre 2012
Publication
du nombre d'actions composant le capital et du nombre total de droits de vote
(articles L. 233-8 II du code de commerce et 223-16 du règlement général
Approbation définitive de l'accord transactionnel concernant des procédures de " class action " aux Etats-Unis
Le 5 novembre 2012
Aux Etats-Unis, l'accord transactionnel, signé le 6 mars 2012 et destiné à mettre un terme à l'ensemble des procédures de « class
Final approval of the settlement agreement relating to class action proceedings in the United States
November 5, 2012
In the United States, the settlement agreement signed on March 6, 2012 which shall put an end to all current class action proceedings (with the exception of the claim relating
ACTIVITE DU TROISIEME TRIMESTRE 2012
ACTIVITE DU TROISIEME TRIMESTRE 2012
(Données non auditées)
ACTIVITE CUMULEE A FIN SEPTEMBRE 2012
en milliers d'euros
2011
2012
Var. taux courant 2012/2011
Var. taux
ACTIVITY IN THE THIRD QUARTER OF 2012
ACTIVITY IN THE THIRD QUARTER OF 2012
(Unaudited data)
CUMULATIVE ACTIVITY AS OF THE END OF SEPTEMBER 2012
thousands of euros
2011
2012
Variation at current exchange rates
Variation
Synergy Pharmaceuticals to Present Poster on SP-333, an Agonist of Guanylate Cyclase-C, Highlighting a Novel Approach to Treating Ulcerative Colitis in Humans
Scientific Poster Presentation This Week at ACG 2012
NEW YORK, Oct. 22, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders
Synergy Pharmaceuticals Highlights Mechanistic Features of Plecanatide, a Novel Investigational Drug for Chronic Idiopathic Constipation
Scientific Poster Presentations This Week at ACG 2012 and UEG Week
NEW YORK, Oct. 22, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal
Synergy Pharmaceuticals Initiates Dosing of Healthy Volunteers in Phase I Trial of SP-333, a Second-Generation GC-C Agonist to Treat Ulcerative Colitis
NEW YORK, Oct. 22, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders announced today that on October 19, 2012 the company